Exposing Congressional Drug Abuse Act
- Bill Number
- H.Con.Res. 35
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Congress
- Status
- Introduced
- Latest Action
- 2025-06-05: Referred to the House Committee on House Administration.
- Last Updated
- 2025-06-18T13:40:26Z
AI-Generated Summary
Purpose
This concurrent resolution, titled the "Exposing Congressional Drug Abuse Act," aims to promote accountability and transparency among members of Congress by mandating their participation in a program for random testing to detect illegal use of controlled substances (drugs regulated under federal law, like marijuana or cocaine, that are illegal without a prescription).
Key Provisions
- Mandatory Participation: Every Member of the House of Representatives and Senate, including Delegates and the Resident Commissioner, must join the drug testing program.
- Testing Frequency and Nature: Members undergo one random drug test per term (e.g., every two years for House members or six years for Senators). Tests are unannounced, periodic, and not based on specific suspicions.
- Handling Positive Results: A "confirmed positive result" (an initial positive test verified by a second test using a different method and certified by a contracted medical review officer, excluding legal or prescribed drugs) is reported to:
- The member themselves.
- The House Ethics Committee (for House members) or Senate Select Committee on Ethics (for Senators) for review under existing chamber rules.
- Refusal Consequences: Ethics Committees must publicly identify members who refuse to participate and take appropriate actions against them.
- Cost Recovery: Members must reimburse their chamber for the test costs.
- Implementation: The House Administration Committee and Senate Rules and Administration Committee will create necessary rules and regulations.
- Definitions:
- Confirmed positive result: As described above, ensuring accuracy and excluding lawful medications.
- Controlled substance: Defined under the federal Controlled Substances Act (21 U.S.C. 802).
- Random drug test: Unannounced and suspicion-free.
Significant Changes to Existing Law
This resolution introduces a new internal congressional program for random drug testing, which does not currently exist for members of Congress. As a concurrent resolution (a measure passed by both chambers to express joint intent or set procedural rules), it would not create enforceable federal law but could establish binding ethics guidelines within Congress if adopted. It builds on existing ethics rules by adding specific drug testing mandates and public disclosure requirements for non-compliance.
Potential Impacts
- On Government Agencies: Ethics Committees would gain new responsibilities for reviewing and disclosing test results or refusals, potentially increasing administrative workload. House and Senate administrative committees would need to oversee program setup, including contracting medical reviewers.
- On Citizens: Could enhance public trust in Congress by promoting transparency and deterring illegal drug use among lawmakers, though it might not directly affect everyday citizens beyond influencing perceptions of government integrity.
- On International Relations: No direct impacts, as this is a domestic internal congressional matter.
Main Stakeholders Affected
- Members of Congress: Directly subject to testing, potential disclosures, and financial reimbursement, affecting their privacy and professional reputations.
- Congressional Committees: House Ethics, Senate Ethics, House Administration, and Senate Rules and Administration Committees, which must implement, review, and enforce the program.
- Public and Oversight Groups: Taxpayers (via indirect funding of the program) and watchdog organizations, who may benefit from increased accountability.
Notable Legal, Constitutional, or Political Implications
- Legal: Relies on Congress's constitutional authority to regulate its own members (Article I), but could raise privacy concerns under the Fourth Amendment (protection against unreasonable searches), though voluntary participation in government roles might limit challenges. Confirmed positives trigger ethics reviews, not automatic penalties, preserving due process.
- Constitutional: As an internal rule, it avoids broader statutory conflicts but could set a precedent for self-regulation on personal conduct.
- Political: May polarize opinions, with supporters viewing it as a step toward ethical reform and critics seeing it as intrusive or symbolic. Public disclosures could influence elections or party dynamics, potentially deterring candidates or exposing vulnerabilities. If not adopted, it highlights ongoing debates on congressional accountability.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2025-06-05: Referred to the House Committee on House Administration.
- 2025-06-05: Submitted in House
- 2025-06-05: Submitted in House
Bill Versions
- Exposing Congressional Drug Abuse Act — issued 2025-06-05 — PDF (4 pages)